Literature DB >> 8304722

Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas.

A Chan1, F Wong, M Arumanayagam.   

Abstract

Serum copper and caeruloplasmin concentrations are elevated in various carcinomas, but it is not known whether the rise in serum copper is due to elevation of caeruloplasmin alone or whether it is also due to the elevation of 'free' copper. We therefore determined ultrafiltrable copper to answer this question. Serum ultrafiltrate was prepared using the Amicon micropartition system and ultrafiltrable (free) copper was determined by flameless atomic absorption spectrophotometry. Serum total copper was determined by flame atomic absorption spectrometry and caeruloplasmin by rate nephelometry. There was no significant difference in the ultrafiltrable copper concentration between patients with gynaecological tumours and control subjects. However, total copper and caeruloplasmin concentrations were significantly elevated in cancer patients compared with control subjects. In contrast to total copper and caeruloplasmin concentrations, ultrafiltrable copper concentrations showed no significant increase with increase in the stage of the cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8304722     DOI: 10.1177/000456329303000603

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  13 in total

1.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

Review 2.  Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer.

Authors:  S M Hadi; M F Ullah; A S Azmi; A Ahmad; U Shamim; H Zubair; H Y Khan
Journal:  Pharm Res       Date:  2010-01-30       Impact factor: 4.200

3.  Caeruloplasmin isoforms in Wilson's disease in neonates.

Authors:  G F Chowrimootoo; H Scowcroft; C A Seymour
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

4.  A high resolution PIXE measurement for blood plasma ultrafiltrate. Application to loosely bound copper.

Authors:  T Kupila-Rantala; J T Dabek; M Hyvönen-Dabek
Journal:  Biol Trace Elem Res       Date:  1996 Oct-Nov       Impact factor: 3.738

5.  Overcoming platinum resistance through the use of a copper-lowering agent.

Authors:  Siqing Fu; Aung Naing; Caroline Fu; Macus Tien Kuo; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

6.  Serum glycoconjugates and ceruloplasmin in cancer of uterine cervix.

Authors:  Sharmila Upadhya; Subramanya Upadhya; K S Prabhu
Journal:  Indian J Clin Biochem       Date:  2002-01

7.  Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.

Authors:  Xia Zhang; Caifeng Bi; Yuhua Fan; Qiuzhi Cui; Di Chen; Yan Xiao; Q Ping Dou
Journal:  Int J Mol Med       Date:  2008-11       Impact factor: 4.101

8.  Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.

Authors:  Siqing Fu; Ming-Mo Hou; Jennifer Wheler; David Hong; Aung Naing; Apostolia Tsimberidou; Filip Janku; Ralph Zinner; Sarina Piha-Paul; Gerald Falchook; Macus Tien Kuo; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2013-12-05       Impact factor: 3.850

9.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou
Journal:  Breast Cancer Res       Date:  2005-09-20       Impact factor: 6.466

Review 10.  Phytoagents for cancer management: regulation of nucleic acid oxidation, ROS, and related mechanisms.

Authors:  Wai-Leng Lee; Jing-Ying Huang; Lie-Fen Shyur
Journal:  Oxid Med Cell Longev       Date:  2013-12-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.